Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 1/2020

01-02-2020 | Shingles | Therapy in Practice

Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review

Author: Lorraine Larsen Rosamilia

Published in: American Journal of Clinical Dermatology | Issue 1/2020

Login to get access

Abstract

Herpes zoster (HZ) is a common cutaneous entity with protean clinical presentations, management options, complication rates, and prevention strategies, all of which are rife with dogma. During an inpatient consultation for HZ, have you ever been approached by a frantic staff or family member, worried that a pregnant, elderly, or infant contact will be ‘infected’ if they get too close? Have your patients ever asked you about their risk of having HZ twice, or claimed that they have frequent ‘recurrences’? In what timeline should antiviral therapy be employed? Is there evidence for prednisone or gabapentin in acute HZ treatment? Who should be vaccinated against HZ and what are the benefits and risks? In case-based form, these and other complex but common scenarios will be examined using clinical and viral mechanistic clues, along with updated treatment and prevention guidelines, to provide a modern HZ case management compendium, comprehensive of the diverse age and health populations now presenting with this condition.
Literature
1.
Brisson M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14.PubMedPubMedCentral
2.
Yawn BP, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.PubMed
3.
Kawai K, et al. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016;63(2):221–6.PubMedPubMedCentral
4.
Lim HW, et al. The burden of skin disease in the United States. J Am Acad Dermatol. 2017;76(5):958–72.e2.PubMed
5.
Dworkin RH, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26.PubMed
6.
Wood MJ, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896–900.PubMed
7.
McKendrick MW, et al. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed). 1986;293:1529–32.
8.
Whitley RJ, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376–83.PubMed
9.
Zhang M, et al. A meta-analysis of therapeutic efficacy and safety of gabapentin in the treatment of postherpetic neuralgia from randomized controlled trials. Biomed Res Int. 2018;2018:7474207.PubMedPubMedCentral
10.
Feli KH, et al. Update in herpes zoster prevention and the role of dermatologists. J Drugs Dermatol. 2019;18(1):18–22.PubMed
11.
Nair PA. Herpes zoster: mistaken for radiculopathy and back pain. J Indian Med Assoc. 2012;110(6):399.PubMed
12.
Böer A, et al. Refining criteria for diagnosis of cutaneous infections caused by herpes viruses through correlation of morphology with molecular pathology. Indian J Dermatol Venereol Leprol. 2006;72(4):270–5.PubMed
13.
Morgan R, King D. Characteristics of patients with shingles admitted to a district general hospital. Postgrad Med J. 1998;74(868):101–3.PubMedPubMedCentral
14.
Brănişteanu DE, et al. Clinical-epidemiological trends of herpes zoster: a 5-year study. Rev Med Chir Soc Med Nat Iasi. 2014;118(3):817–22.PubMed
15.
Aggarwal S, Radhakrishnan S. A clinico-epidemiological study of herpes zoster. Med J Armed Forces India. 2016;72(2):175–7.PubMed
16.
Abdul E, Pavithran K. Herpes zoster: a clinical study in 205 patients. Ind J Dermatol. 2011;56:529–32.
17.
Shors T. Herpesviruses: Varicella Zoster Virus (VZV). In: Shors T, editor. Understanding viruses. 2nd ed. Burlington: Jones & Bartlett; 2011. p. 459.
18.
19.
20.
21.
Reynolds MA, et al. Varicella seroprevalence in the US: data from the National Health and Nutrition Examination Survey, 1999–2004. Public Health Rep. 2010;125(6):860–9.PubMedPubMedCentral
22.
23.
24.
Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018;41(2):95–105.PubMed
25.
Harpaz R, Leung JW. The epidemiology of herpes zoster in the United States during the era of varicella and herpes zoster vaccines: changing patterns among older adults. Clin Infect Dis. 2019;69(2):341–4.PubMed
26.
Ragozzino MW, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61:310–6.PubMed
27.
Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806–21.PubMed
28.
29.
Feder HM, Hoss DM. Herpes zoster in otherwise healthy children. Pediatr Infect Dis J. 2004;23:451–7.PubMed
30.
David TJ, Williams ML. Herpes zoster in infancy. Scand J Infect Dis. 1979;11:185–6.PubMed
31.
Forbes H, et al. Quantification of risk factors for herpes zoster: population-based case–control study. BMJ. 2014;348:g2911.PubMedPubMedCentral
32.
33.
34.
Weinmann S, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis. 2013;208:1859–68.PubMed
35.
Weinmann S, et al. Incidence of herpes zoster among children: 2003–2014. Pediatrics. 2019;144(1):e20182917.PubMed
36.
Harpaz R. Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. Expert Rev Vaccines. 2019;18(8):793–811.PubMed
37.
Wutzler P, et al. Herpes zoster in the context of varicella vaccination—an equation with several variables. Vaccine. 2018;36(46):7072–82.PubMed
38.
Lewis DJ, et al. Atypical disseminated herpes zoster: management guidelines in immunocompromised patients. Cutis. 2017;100(5):321, 324, 330.
39.
40.
Tilley DH, et al. Disseminated verrucous varicella zoster with exclusive follicular involvement. Arch Dermatol. 2012;148(3):405–7.PubMed
41.
Wauters O, et al. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol. 2012;66(6):e217–27.PubMed
42.
Prelog M, et al. Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients. Vaccine. 2013;31:2420–6.PubMed
43.
Gilbert L, et al. Herpes zoster rates continue to decline in people living with human immunodeficiency virus but remain higher than rates reported in the general US population. Clin Infect Dis. 2019;69(1):155–8.PubMed
44.
Insinga RP, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748–53.PubMedPubMedCentral
45.
Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–57.PubMed
46.
Ljubojević HS, et al. Genital herpes zoster as possible indicator of HIV infection. Acta Dermatovenerol Croat. 2018;26(4):337–8.
47.
Dayan RR, Peleg R. Herpes zoster—typical and atypical presentations. Postgrad Med. 2017;129(6):567–71.PubMed
48.
Chughtai K, et al. Topical 5-fluorouracil associated skin reaction. Oxf Med Case Rep. 2017;2017(8):omx043.
49.
Wilson DA, et al. Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol. 2012;50(12):4120–2.PubMedPubMedCentral
50.
Dobec M, et al. Serology and serum DNA detection in shingles. Swiss Med Wkly. 2008;138(3–4):47–51.PubMed
51.
Balfour HH, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983;308:1448–53.PubMed
52.
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2 Suppl):S3–12.PubMed
53.
Tyring S, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:89–96.PubMed
54.
Beutner KR, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546–53.PubMedPubMedCentral
55.
Chen N, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.
56.
Stein GE. Pharmacology of new antiherpes agents: famciclovir and valacyclovir. J Am Pharm Assoc (Wash). 1997;37(2):157–63.
57.
Ormrod D, Goa K. Valaciclovir: a review of its use in the management of herpes zoster. Drugs. 2000;59(6):1317–40.PubMed
58.
Madkan VK, et al. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older. J Cutan Med Surg. 2007;11(3):89–98.PubMed
59.
Barnabas RV, et al. Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: results of a randomized clinical trial. J Infect Dis. 2016;213(4):551–5.PubMed
60.
Chen N, et al. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2010;12:CD005582.
61.
Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2013;3:CD005582.
62.
Dworkin RH, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009;142(3):209–17.PubMed
63.
Bulilete O, et al. Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: a double blind, randomized controlled trial. PLoS One. 2019;14(6):e0217335.PubMedPubMedCentral
64.
Ghaznawi N, et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology. 2011;118(11):2242–50.PubMed
65.
Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67(2–3):241–51.PubMed
66.
Thyregod HG, et al. Natural history of pain following herpes zoster. Pain. 2007;128(1–2):148–56.PubMed
67.
Zhu SM, et al. Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia. J Zhejiang Univ Sci B. 2009;10(8):625–30.PubMedPubMedCentral
68.
Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain. 2001;92:139–45.PubMed
69.
Kawai K, et al. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.PubMedPubMedCentral
70.
Hempenstall K, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):e164.PubMedPubMedCentral
71.
Johnson P, et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013;33(1):35–44.PubMed
72.
Nagasako EM, et al. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol. 2002;46(6):834–9.PubMed
73.
Drolet M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11(11):1211–21.PubMed
74.
Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134–42.PubMed
75.
Galer BS, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533–8.PubMed
76.
Lin CS, et al. Interventional treatments for postherpetic neuralgia: a systematic review. Pain Physician. 2019;22(3):209–28.PubMed
77.
78.
79.
80.
Opstelten W, et al. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine. 2009;27(2):192–6.PubMed
81.
Schmader KE, Shingles Prevention Study Group, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.PubMedPubMedCentral
82.
83.
Vink P, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301–12.PubMed
84.
Berkowitz EM, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–87.PubMed
85.
Bastidas A, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–33.PubMedPubMedCentral
86.
Dooling KL, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–8.PubMedPubMedCentral
87.
Dagnew AF, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000.PubMed
88.
Baumrin E, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019;81(1):102–10.PubMed
89.
Failla V, et al. Herpes zoster in patients treated with biologicals. Dermatology. 2012;224(3):251–6.PubMed
90.
Zaal MJ, et al. Longitudinal analysis of varicella-zoster virus DNA on the ocular surface associated with herpes zoster ophthalmicus. Am J Ophthalmol. 2001;131:25–9.PubMed
91.
92.
Tseng HF, et al. Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine. Clin Infect Dis. 2014;58(8):1125–8.PubMedPubMedCentral
93.
Guffey DJ. Herpes zoster following varicella vaccination in children. Cutis. 2017;99(3):207–11.PubMed
94.
Peterson N, Goodman S, Peterson M, et al. Herpes zoster in children. Cutis. 2016;98:94–5.
95.
Lopez AS, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis. 2008;197(5):646–53.PubMed
96.
Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1–40.PubMed
97.
Goulleret N, et al. Safety profile of live varicella virus vaccine (Oka/Merck): 5-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine. 2010;28(36):5878–82.PubMed
98.
Pryde PG. Varicella zoster virus in pregnancy. In: Craigo SD, Baker ER, editors. Medical Complications in Pregnancy. NewYork: McGraw-Hill; 2005. p. 383–98.
99.
Müllegger RR, et al. Skin infections in pregnancy. Clin Dermatol. 2016;34(3):368–77.PubMed
100.
Hayward K, et al. Management of herpes zoster (shingles) during pregnancy. J Obstet Gynaecol. 2018;38(7):887–94.PubMed
101.
Sauerbrei A, Wutzler P. Placental boost to varicella-zoster antibodies in the newborn. J Perinat Med. 2002;30(4):345–8.PubMed
102.
Casanova RG, et al. Herpes zoster in immunocompetent pregnant women and their perinatal outcome. Ginecol Obstet Mex. 2004;72:63–7.
103.
Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010;304(8):859–66.PubMed
104.
Schafer R, et al. Herpes zoster in pregnancy. J Midwifery Womens Health. 2019;64(2):230–5.PubMed
105.
Hernandez PO, et al. Family history and herpes zoster risk in the era of shingles vaccination. J Clin Virol. 2011;52(4):344–8.PubMed
Metadata
Title
Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review
Author
Lorraine Larsen Rosamilia
Publication date
01-02-2020
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 1/2020
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-019-00483-1

Other articles of this Issue 1/2020

American Journal of Clinical Dermatology 1/2020 Go to the issue

Original Research Article

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial

Systematic Review

Effects of Zinc Supplementation on Inflammatory Skin Diseases: A Systematic Review of the Clinical Evidence

Review Article

Artificial Intelligence in Dermatology—Where We Are and the Way to the Future: A Review

Original Research Article

Atopic Dermatitis and Celiac Disease: A Cross-Sectional Study of 116,816 Patients

Review Article

Female Androgenetic Alopecia: An Update on Diagnosis and Management

Short Communication

Characterization and Analysis of the Skin Microbiota in Rosacea: A Case–Control Study